NCT06361888 2025-12-30
A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer
Hutchmed
Phase 2/3 Recruiting
Clinical Trials
8 trialsNCT06759090 2025-01-06
Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer
Zhejiang University
Phase 2 Not yet recruiting
NCT05218889 2024-12-31
Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer
Chinese PLA General Hospital
Phase 1/2 Recruiting
NCT04674956 2024-04-02
A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer
RenJi Hospital
Phase 3 Recruiting
NCT06326736 2024-03-22
Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer
Jinling Hospital, China
Phase EARLY_PHASE1 Recruiting
NCT04420130 2022-10-04
A Trial of Camrelizumab Combined With Ablation and Chemotherapy in Patients With Pancreatic Cancer Liver Metastasis（SHR-1210-HLJ-009）
Harbin Medical University
Phase NA Withdrawn
NCT04498689 2020-08-04
Efficacy and Safety of Camrelizumab Combined With Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer
Fudan University
Phase 2 Unknown
NCT04415385 2020-06-04
The Combination of Camrelizumab and Apatinib as Second-line Therapy for Advanced Pancreatic Carcinoma
Zhejiang Cancer Hospital
Phase 2 Unknown